as of 12-04-2025 3:46pm EST
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 11.1M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 6.8M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.12 - $12.76 | Next Earning Date: | 11-19-2025 |
| Revenue: | N/A | Revenue Growth: | 122.22% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
See how PFSA stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "PFSA Profusa Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.